Brigatinib-d11
Brigatinib-d11 (AP-26113-d11) is deuterium labeled Brigatinib. Brigatinib (AP-26113) is a highly potent, selective and orally active ALK inhibitor, with an IC50 of 0.6 nM. Brigatinib can be used for research of NSCLC[1].
Product Specifications
CAS Number
2055306-76-6
Product Name Alternative
AP-26113-d11
UNSPSC
12352005
Target
Anaplastic lymphoma kinase (ALK) ; Isotope-Labeled Compounds
Related Pathways
Others; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
COC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)P(C)(C)=O)=N2)C=CC(N4CCC(N5C([2H])([2H])C([2H])([2H])N(C([2H])([2H])C5([2H])[2H])C([2H])([2H])[2H])CC4)=C1
Molecular Formula
C29H28D11ClN7O2P
Molecular Weight
595.16
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Huang WS, et al. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. J Med Chem. 2016 May 26;59 (10) :4948-64.|[3]Zhang S, et al. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016 Nov 15;22 (22) :5527-5538|[4]Siaw JT, et al. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. Oncotarget. 2016 May 17;7 (20) :29011-22
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15321460 1 Vial
Lentiviral human CITED2 shRNA (UAS) - Lentiviral human CITED2 shRNA (UAS, RFP) plasmid
Sign In for Pricing
View Details